Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 5/20 | 0.58 |
| ▸ | MMP1 | P03956 | 4/20 | 0.58 |
| ▸ | MMP3 | P08254 | 3/20 | 0.58 |
| ▸ | MMP7 | P09237 | 2/20 | 0.58 |
| ▸ | MMP9 | P14780 | 2/20 | 0.58 |
| ▸ | MMP2 | P08253 | 2/20 | 0.58 |
| ▸ | MMP8 | P22894 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | USP2 | O75604 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | BLM | P54132 | 1/20 | 0.44 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7250977 | 0.92 | MMP13 (0.60) | MMP13MMP1MMP3MMP7MMP9 | |
| SCHEMBL6289737 | 0.82 | MMP13 (0.58) | MMP13MMP1MMP3MMP7MMP9 | |
| SCHEMBL6291043 | 0.80 | MMP13 (0.52) | MMP13MMP1MMP3MMP7MMP9 | |
| SCHEMBL6289785 | 0.79 | MMP13 (0.53) | MMP13MMP1MMP3MMP7MMP9 | |
| SCHEMBL7410002 | 0.78 | MMP13 (0.48) | MMP13MMP1MMP3MMP7MMP9 | |
| SCHEMBL6293732 | 0.78 | MMP2 (0.52) | MMP13MMP1MMP3MMP7MMP9 | |
| SCHEMBL643982 | 0.76 | MMP1 (0.55) | MMP13MMP1MMP3MMP7MMP9 | |
| SCHEMBL6289787 | 0.75 | MMP13 (0.52) | MMP13MMP1MMP3MMP7MMP9 | |
| SCHEMBL7253756 | 0.74 | MMP1 (0.61) | MMP13MMP1MMP3MMP7MMP9 | |
| SCHEMBL7341184 | 0.74 | MMP1 (0.56) | MMP13MMP1MMP9MMP2MMP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6949545-B2 | Heterocyclic side chain containing, n-substituted metalloprotease inhibitors | THE PROCTER & GAMBLE COMPANY (US) | 2005-09-27 | — | — | US | disclosed |
| US-20040127498-A1 | Heterocyclic side chain containing, n-substituted metalloprotease inhibitors | THE PROCTER & GAMBLE COMPANY | 2004-07-01 | — | — | US | disclosed |
| US-20030139414-A1 | Heterocyclic side chain containing, n-substituted metalloprotease inhibitors | THE PROCTER & GAMBLE COMPANY | 2003-07-24 | — | — | US | disclosed |
| EP-1265864-A1 | HETEROCYCLIC SIDE CHAIN CONTAINING, N-SUBSTITUTED METALLOPROTEASE INHIBITORS | THE PROCTER & GAMBLE COMPANY (US) | 2002-12-18 | — | — | EP | disclosed |
| WO-2001070691-A1 | HETEROCYCLIC SIDE CHAIN CONTAINING, N-SUBSTITUTED METALLOPROTEASE INHIBITORS | THE PROCTER & GAMBLE COMPANY (US) | 2001-09-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030139414-A1 | Heterocyclic side chain containing, n-substituted metalloprotease inhibitors | MME, MMP2, MMP9 | MMP13 38/4885MMP1 15/4885MMP3 13/4885 |
| US-20040127498-A1 | Heterocyclic side chain containing, n-substituted metalloprotease inhibitors | MME, MMP2, MMP9 | MMP13 38/4885MMP1 15/4885MMP3 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.